Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction
Author(s): Elmir Omerovic | Truls Råmunddal | Per Albertsson | et alJournal: Vascular Health and Risk Management ISSN 1176-6344
Volume: 2010; Issue: default; Start page: 657; Date: 2010;
Original page
ABSTRACT
Elmir Omerovic, Truls Råmunddal, Per Albertsson, Mikael Holmberg, Per Hallgren, Jan Boren, Lars Grip, Göran MatejkaDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg, SwedenBackground: The aim of this study was to evaluate the effect of levosimendan on mortality in cardiogenic shock (CS) after ST elevation myocardial infarction (STEMI).Methods and results: Data were obtained prospectively from the SCAAR (Swedish Coronary Angiography and Angioplasty Register) and the RIKS-HIA (Register of Information and Knowledge about Swedish Heart Intensive Care Admissions) about 94 consecutive patients with CS due to STEMI. Patients were classified into levosimendan-mandatory and levosimendan-contraindicated cohorts. Inotropic support with levosimendan was mandatory in all patients between January 2004 and December 2005 (n = 46). After the SURVIVE and REVIVE II studies were presented, levosimendan was considered contraindicated and was not used in consecutive patients between December 2005 and December 2006 (n = 48). The cohorts were similar with respect to pre-treatment characteristics and concomitant medications. There was no difference in the incidence of new-onset atrial fibrillation, in-hospital cardiac arrest and length of stay at the coronary care unit. There was no difference in adjusted mortality at 30 days and at one year.Conclusion: The use of levosimendan neither improves nor worsens mortality in patients with CS due to STEMI. Well-designed randomized clinical trials are needed to define the role of inotropic therapy in the treatment of CS.Keywords: shock, myocardial infarction, inotropic agents, heart failure, pharmacology
Add to my list
My list